Selective Janus Kinase Inhibition Preserves Interferon-Λ-mediated Antiviral Responses

Inflammatory diseases are frequently treated with Janus kinase (JAK) inhibitors to diminish cytokine signaling. These treatments can lead to inadvertent immune suppression and may increase the risk of viral infection. Tyrosine kinase 2 (TYK2) is a JAK family member required for efficient type I inte...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Sci Immunol
Egile Nagusiak: Schnepf, Daniel, Crotta, Stefania, Thamamongood, Thiprampai, Stanifer, Megan, Polcik, Laura, Ohnemus, Annette, Vier, Juliane, Jakob, Celia, Llorian, Miriam, Gad, Hans Henrik, Hartmann, Rune, Strobl, Birgit, Kirschnek, Susanne, Boulant, Steeve, Schwemmle, Martin, Wack, Andreas, Staeheli, Peter
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2021
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7610871/
https://ncbi.nlm.nih.gov/pubmed/33990378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciimmunol.abd5318
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak